NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovere

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NAS

Allworth Financial LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NB

Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a d

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but p

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and e

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, maki

BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during

Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences.

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessi

ABN AMRO Bank N.V. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) du

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock fell almost 5% on Wednesday before recovering after

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi sy

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrat

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrat

Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR,

Cetera Investment Advisers increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and inv

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a B

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and

Glenmede Trust Co. NA reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 3.8% in

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W

TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises

Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipe

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overwe

Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Ove

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rai

Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises

Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises th

Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript

The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarte

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the a

Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rais

Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market P

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical st

Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated impr

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHta

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets